Inhibitors of 5α-Reductase in the Treatment of Benign Prostatic Hyperplasia
February 2006
in “
Current pharmaceutical design
”
Studysummary This review discusses the use of 5α-reductase inhibitors in treating benign prostatic hyperplasia, highlighting their long-term effectiveness and benefits when combined with α1-adrenergic antagonists; it reports no new clinical results.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on eurekaselect.com →